BridgeBio Pharma (BBIO) revenue

Revenue · fiscal 2025
$502.08M

BridgeBio Pharma (BBIO) reported revenue of $502.08M in fiscal 2025 (the year ended December 31, 2025). That is 126.3% higher than the $221.90M of fiscal 2024. Figures as of 18 Nov 2026, 12:00 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$502.08M
Change on fiscal 2024
+126.3%
Growth, 5 years
+127.4% a year
Highest on record
$502.08Mfiscal 2025
Lowest on record
$8.25Mfiscal 2020
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

BridgeBio Pharma revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 127.4% a year. Across the 7 fiscal years on record (2019–2025), the highest was $502.08M in fiscal 2025 and the lowest $8.25M in fiscal 2020.

History · 7 fiscal years

Revenue by fiscal year

BridgeBio Pharma revenue, year by year

BridgeBio Pharma (BBIO) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$502.08M 126.3% up
2024$221.90M 2,285.3% up
2023$9.30M 88.0% down
2022$77.65M 11.4% up
2021$69.72M 745.1% up
2020$8.25M 79.7% down
2019$40.56M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of BridgeBio Pharma and comparable companies
CompanyRevenueFiscal year
ICON ICLR$8.25B2025
Jazz Pharmaceuticals JAZZ$4.27B2025
Solventum SOLV$8.33B2025
BridgeBio Pharma BBIO$502.08M2025
Summit Therapeutics SMMT$705.00K2022
Glaukos GKOS$507.44M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BBIO

BridgeBio Pharma, figure by figure

BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value

BridgeBio Pharma revenue: questions and answers

What is BridgeBio Pharma's revenue?

BridgeBio Pharma (BBIO) reported revenue of $502.08M in fiscal 2025 (the year ended December 31, 2025). That is 126.3% higher than the $221.90M of fiscal 2024.

What is the growth rate of BridgeBio Pharma's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 127.4% a year.

What are the highest and lowest revenue figures on record for BridgeBio Pharma?

Across the 7 fiscal years on record (2019–2025), the highest was $502.08M in fiscal 2025 and the lowest $8.25M in fiscal 2020.

How is BridgeBio Pharma's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For BridgeBio Pharma it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BridgeBio Pharma (BBIO) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/BBIO/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.